Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1988 Jul-Aug;61(4):327-38.

Clinical management of patients with invasive cervical cancer following a negative Pap smear

Affiliations
Review

Clinical management of patients with invasive cervical cancer following a negative Pap smear

P E Schwartz et al. Yale J Biol Med. 1988 Jul-Aug.

Abstract

Among 535 patients with invasive cervical carcinoma seen between January 1975 and June 1986, 26 were found to have developed the disease within six months (65 percent), 35 within 12 months (88 percent), 37 within 13 months (93 percent), and three developed the disease within 17 months after a negative Pap smear. Eighty-eight percent of these 40 patients were under age 40 at diagnosis. Rapidly progressive cancers are highly resistant to radiation therapy. Seven stage IB patients treated only with radiation died within nine to 29 months after initial therapy. By contrast, 15 patients treated by radical hysterectomy and four by radical hysterectomy and post-surgical radiation were alive with no evidence of disease from six to 109 months after surgery (median, 30 months). Six of nine patients with stage II to IV disease treated with radiation have died; the remaining three are alive. One patient is well 14 months after therapy, but two others have developed metastases seven and 12 months after treatment. Surprisingly, 37 of 40 patients had symptoms of pain, bleeding, and discharge at the initial diagnosis, but their physicians had a false sense of security because of a recent negative Pap smear. Early biopsy diagnosis and radical hysterectomy with bilateral pelvic lymphadenectomy is the most effective management for this cancer.

PubMed Disclaimer

References

    1. Lancet. 1978 May 13;1(8072):1031-2 - PubMed
    1. Am J Obstet Gynecol. 1975 Apr 15;121(8):1024-8 - PubMed
    1. J Obstet Gynaecol Br Commonw. 1968 Apr;75(4):392-404 - PubMed
    1. Trans Pac Coast Obstet Gynecol Soc. 1971;39(0):114-21 - PubMed
    1. Cancer Res. 1976 Feb;36(2 pt 2):783-91 - PubMed

MeSH terms